Introduction
[ 6 6 _ T D $ D I F F ] Posttraumatic stress disorder (PTSD) is a complex psychiatric disorder that can develop after experiencing a severe trauma. In the US, the overall prevalence of PTSD is 8%, with the rate increasing up to 22% in veterans that have been deployed to Iraq or Afghanistan [1] . PTSD is mainly characterized by persistent re-experiencing of the traumatic event through spontaneous memories or environmental cues, avoidance of trauma-related cues, and hyperarousal. To date, the only FDA-approved pharmacological treatments, selective serotonin reuptake inhibitors (SSRIs), have limited efficacy, with only $60% of patients responding to treatment and 20-30% achieving full remission [2] , supporting the urgency in identifying prognostic biomarkers and novel pharmacological therapies.
Clinical evidence for link between inflammation and PTSD symptoms
In the last decade, mounting evidence supports a role for inflammation as a potential pathophysiological mechanism underlying PTSD. Elevated serum levels of proinflammatory cytokines interleukin-1b (IL-1b), interleukin-6 (IL-6) and tumor necrosis factor-a (TNF-a), and the complement protein C-reactive protein (CRP) are consistently observed in PTSD individuals compared to healthy controls and combat-exposed controls [3] [4] [5] . The levels of pro-inflammatory cytokines and CRP are positively correlated with severity of symptoms [5] . These data suggest that inflammation is present during high symptom state, but do not address if inflammation plays a role in PTSD risk. A prospective study (Marine Resiliency Study) of PTSD development in service members deployed to combat zones reported that high levels of plasma CRP collected before deployment were associated with increased risk for developing PTSD after combat [6 [ 5 9 _ T D $ D I F F ] ]. Similarly, those that developed PTSD after combat exhibited altered gene expression patterns in peripheral immune cells collected before combat compared to those that did not go on to develop PTSD after combat [7] . Putatively functional mutations in immune genes (CRP) are also associated with increased risk for PTSD [8 ] . Finally, higher glucocorticoid-dependent cytokine production and T-cell proliferation before deployment is associated with increased PTSD symptoms after combat [9] . These findings suggest that immune factors might not only be markers for symptom state, but also contribute to pre-existing risk for PTSD upon trauma exposure. Overall, these findings support the emerging theory that alterations in the immune system may promote the development of PTSD symptoms, but the causal link between symptoms and inflammation remains to be understood. It is unclear if immune abnormalities increase risk for behavioral symptoms of PTSD (e.g., represent a risk trait) or are simply an epiphenomenon of other risk mechanisms (e.g., abnormal glucocorticoid signaling [10] , high trauma burden, or poor health choices) or if trauma itself causes a disruption of the immune system leading to PTSD symptoms (e.g., stress-induced inflammation). It is also unclear how much and if peripheral immune signaling, the predominant
